Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
PR Newswire•22/09/2026•09:20 ET
0
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement PR Newswire
Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets
Get started
Create a free account to read the full story and Whiz Insights.